Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH gets conflict attention

This article was originally published in The Tan Sheet

Executive Summary

The HHS Office of Inspector General's planned study of FDA's oversight of conflicts of interest for drug, biologic and device clinical investigators is on hold in fiscal 2007 pending an NIH conflict-of-interest study, Inspector General Daniel Levinson says in a recent letter to House Energy and Commerce Committee Chairman John Dingell, D-Mich. OIG expects in early 2008 to release a draft report that evaluates NIH's conflict-of-interest policies, procedures and internal investigations. FDA in March this year issued a more stringent draft guidance for determining conflict of interest and eligibility for participation in its advisory committee meetings. The proposed revisions increase the stringency of current guidance by adding a flat $50,000 threshold for financial interest in a company whose product is being reviewed by the committee (1"The Tan Sheet," March 26, 2007, p. 7). Former FDA Commissioner Lester Crawford pleaded guilty to conflict of interest and false writings charges for holding shares in firms regulated by the agency and failing to report those holdings (2"The Tan Sheet," Oct. 23, 2006, p. 5)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel